Benjamin Bonavida
YOU?
Author Swipe
View article: Preface: Probiotics and Implications in Oncogenesis
Preface: Probiotics and Implications in Oncogenesis Open
View article: The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications
The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications Open
The treatment of cancers with immunotherapies has yielded significant milestones in recent years. Amongst these immunotherapeutic strategies, the FDA has approved several checkpoint inhibitors (CPIs), primarily Anti-Programmed Death-1 (PD-…
View article: Relationship of Signaling Pathways between RKIP Expression and the Inhibition of EMT-Inducing Transcription Factors SNAIL1/2, TWIST1/2 and ZEB1/2
Relationship of Signaling Pathways between RKIP Expression and the Inhibition of EMT-Inducing Transcription Factors SNAIL1/2, TWIST1/2 and ZEB1/2 Open
Untreated primary carcinomas often lead to progression, invasion and metastasis, a process that involves the epithelial-to-mesenchymal transition (EMT). Several transcription factors (TFs) mediate the development of EMT, including SNAIL1/S…
View article: Therapeutic Implications of Targeting YY1 in Glioblastoma
Therapeutic Implications of Targeting YY1 in Glioblastoma Open
The transcription factor Yin Yang 1 (YY1) plays a pivotal role in the pathogenesis of glioblastoma multiforme (GBM), an aggressive form of brain tumor. This review systematically explores the diverse roles of YY1 overexpression and activit…
View article: Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications Open
Innovations in cancer immunotherapy have resulted in the development of several novel immunotherapeutic strategies that can disrupt immunosuppression. One key advancement lies in immune checkpoint inhibitors (ICIs), which have shown signif…
View article: Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1 Open
During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and r…
View article: In Loving Memory of Dr. Rana Lynn Samuels-Ofran and Dr. Beth Sharon Samuels
In Loving Memory of Dr. Rana Lynn Samuels-Ofran and Dr. Beth Sharon Samuels Open
View article: Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells
Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells Open
Cancer is a leading cause of death among the various diseases encountered in humans. Cancer is not a single entity and consists of numerous different types and subtypes that require various treatment regimens. In the last decade, several m…
View article: Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications
Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications Open
The Raf kinase inhibitor protein (RKIP) has been reported to be underexpressed in many cancers and plays a role in the regulation of tumor cells’ survival, proliferation, invasion, and metastasis, hence, a tumor suppressor. RKIP also regul…
View article: Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Open
Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
View article: Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Open
Supplementary Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
View article: Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Open
Purpose: Rituximab [chimeric anti-CD20 monoclonal antibody], alone or combined with chemotherapy, is used in the treatment of non–Hodgkin's lymphoma (NHL). Rituximab binds to CD20 and inhibits intracellular survival/growth pathways …
View article: Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Data from Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions Open
Purpose: Rituximab [chimeric anti-CD20 monoclonal antibody], alone or combined with chemotherapy, is used in the treatment of non–Hodgkin's lymphoma (NHL). Rituximab binds to CD20 and inhibits intracellular survival/growth pathways …
View article: Supplementary Figures 1-5 from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Supplementary Figures 1-5 from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Supplementary Figures 1-5 from Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
View article: Supplementary Figures 1-5 from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Supplementary Figures 1-5 from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Supplementary Figures 1-5 from Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
View article: Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
View article: Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
View article: Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
Supplementary Figure 1 from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
View article: Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
View article: Data from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Data from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
The novel proteasome inhibitor NPI-0052 has been shown to sensitize tumor cells to apoptosis by various chemotherapeutic drugs and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), although the mechanisms involved are not cl…
View article: Data from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Data from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Durable responses in metastatic melanoma patients remain generally difficult to achieve. Adoptive cell therapy (ACT) with ex vivo engineered lymphocytes expressing high affinity T-cell receptors (TCRα/β) for the melanoma antigen MAR…
View article: Data from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Data from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Durable responses in metastatic melanoma patients remain generally difficult to achieve. Adoptive cell therapy (ACT) with ex vivo engineered lymphocytes expressing high affinity T-cell receptors (TCRα/β) for the melanoma antigen MAR…
View article: Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1<sup>+</sup>/A*0201<sup>+</sup> Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction Open
Supplementary Figure Legends 1-5, Table 1, Methods from Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction
View article: Data from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Data from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
The novel proteasome inhibitor NPI-0052 has been shown to sensitize tumor cells to apoptosis by various chemotherapeutic drugs and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), although the mechanisms involved are not cl…
View article: Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization Open
Supplementary Figure Legend from Pivotal Roles of Snail Inhibition and RKIP Induction by the Proteasome Inhibitor NPI-0052 in Tumor Cell Chemoimmunosensitization
View article: RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer
RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer Open
Raf kinase inhibitor protein (RKIP), previously known as a phosphatidylethanolamine-binding protein (PEBP), was cloned by Yeung et al [...]
View article: The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment
The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment Open
The Raf Kinase Inhibitor Protein (RKIP) is a unique gene product that directly inhibits the Raf/Mek/Erk and NF-kB pathways in cancer cells and resulting in the inhibition of cell proliferation, viability, EMT, and metastasis. Additionally,…
View article: The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis
The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis Open
The expression of inducible nitric oxide synthase (iNOS; NOS2) and derived NO in various cancers was reported to exert pro- and anti-tumorigenic effects depending on the levels of expression and the tumor types. In humans, the breast cance…
View article: Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer
Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer Open
Lung cancer (LC) represents a global threat, being the tumor with the highest mortality rate. Despite the introduction of novel therapies (e.g., targeted inhibitors, immune-checkpoint inhibitors), relapses are still very frequent. Accordin…
View article: Preface
Preface Open